IPHA
Innate Pharma Delivers Strong Progress in FY 2025 Earnings Call, Sets Stage for Future Growth
In a highly anticipated earnings call, Innate Pharma's leadership team delivered a comprehensive update on the company's full-year 2025 performance and strategic priorities. The Q4 2025 conference call provided valuable insights into the company's progress across its core programs and its ambitious plans to